Daré Bioscience Q2 2025: Cash $5.0M, Sildenafil Cream launch on track for Q4 2025, Ovaprene DSMB positive

Dare Bioscience, Inc.

2025-Q2 EPS reported -$0.95 revenue$4,255

Cash of $5.0M at June 30; working capital deficit $12.6M; raised ~$17.6M net from ATM and $6M grant post-quarter.
G&A $2.4M, R&D $1.4M (down 71% YoY) reflecting increased contra R&D from grants.
DARE to PLAY Sildenafil Cream on track for Q4 2025 launch via 503B compounding, targeting near-term revenue.
Ovaprene Phase 3 DSMB recommended continuation no new safety concerns; interim pregnancy rate consistent.
DARE-HRT1 monthly ring pursuing 503B compounding for late 2026 alongside FDA pathway.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.